|
Home:
Web Guide 2: Richard
M Goldberg, MD: Selected references
Selected references
Bleiberg H, Di Leo A. Mortality associated with irinotecan
plus bolus fluorouracil/leucovorin. J Clin Oncol 2002;20(4):1145-6.
No abstract available.
Borner MM et al. Phase II study of capecitabine and oxaliplatin
in first- and second-line treatment of advanced or metastatic colorectal
cancer. J Clin Oncol 2002;20(7):1759-66. Abstract
de Gramont A et al. Leucovorin and fluorouracil with or
without oxaliplatin as first-line treatment in advanced colorectal
cancer. J Clin Oncol 2000;18(16):2938-47. Abstract
de Gramont A et al. Oxaliplatin/5-FU/LV in adjuvant colon
cancer: Safety results of the international randomized MOSAIC trial.
Proc ASCO 2002;Abstract
525.
Diaz-Rubio E et al. Capecitabine (Xeloda) in combination
with oxaliplatin: A phase I, dose-escalation study in patients with
advanced or metastatic solid tumors. Ann Oncol 2002;13(4):558-65.
Abstract
Falcone A et al. Sequence effect of irinotecan and fluorouracil
treatment on pharmacokinetics and toxicity in chemotherapy-naive
metastatic colorectal cancer patients. J Clin Oncol 2001;19(15):3456-62.
Abstract
Gamelin E et al. Prevention of oxaliplatin peripheral
sensory neuropathy by Ca+ gluconate/Mg+ chloride infusions: A retrospective
study. Proc ASCO 2002;Abstract
624.
Gent P, Massey K. An overview of chemotherapy-induced
peripheral sensory neuropathy, focusing on oxaliplatin. Int
J Palliat Nurs 2001;7(7):354-9. Abstract
Goldberg RM et al. N9741: Oxaliplatin (oxal) or CPT-11
+ 5-fluorouracil (5-FU)/leucovorin (LV) or oxal + CPT-11 in advanced
colorectal cancer (CRC). Initial toxicity and response data from
a GI Intergroup study. Proc ASCO 2002;Abstract
511.
Grothey A et al. Phase III study of bolus 5-fluorouracil
(5-FU)/ folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/
FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC).
Proc ASCO 2002;Abstract
512.
Haller DG. Safety of oxaliplatin in the treatment of colorectal
cancer. Oncology 2000;14(12 Suppl 11):15-20. Abstract
Jordan K et al. Randomized phase II trial of capecitabine
plus irinotecan vs capecitabine plus oxaliplatin as first-line therapy
in advanced colorectal cancer (ACRC): Results of an interim analysis.
Proc ASCO 2002;Abstract
2225.
Ledermann JA et al. Recommendation for caution with irinotecan,
fluorouracil, and leucovorin for colorectal cancer. N Engl
J Med 2001;345(2):145-6. No abstract available.
Penz M et al. Subcutaneous administration of amifostine:
A promising therapeutic option in patients with oxaliplatin-related
peripheral sensitive neuropathy. Ann Oncol 2001;12(3):421-2.
No abstract available.
Rothenberg ML et al. Mortality associated with irinotecan
plus bolus fluorouracil/leucovorin: Summary findings of an independent
panel. J Clin Oncol 19:3801-7. Abstract
Saltz LB et al. Irinotecan plus fluorouracil and leucovorin
for metastatic colorectal cancer. Irinotecan Study Group. N
Engl J Med 2000;343(13):905-14. Abstract
Sargent DJ et al. Recommendation for caution with irinotecan,
fluorouracil, and leucovorin for colorectal cancer. N Engl
J Med 2001;345(2):144-5; discussion 146. No abstract available.
Shields AF et al. A phase II trial of oxaliplatin and
capecitabine in patients with advanced colorectal cancer.
Proc ASCO 2002;Abstract
568.
Tabernero J et al. Capecitabine and oxaliplatin in combination
(Xelox) as first-line therapy for patients (pts) with metastatic
colorectal cancer (MCRC): Results of an international multicenter
phase II trial. Proc ASCO 2002;Abstract
531.
Vamvakas L et al. Irinotecan (CPT-11) in combination with
infusional 5-fluorouracil and leucovorin (de Gramont regimen) as
first-line treatment in patients with advanced colorectal cancer:
A multicenter phase II study. Am J Clin Oncol 2002;25(1):65-70.
Abstract
Wilson RH et al. Acute oxaliplatin-induced peripheral
nerve hyperexcitability. J Clin Oncol 2002;20(7):1767-74.
Abstract
Zeuli M et al. Capecitabine and oxaliplatin in advanced
colorectal cancer: A dose-finding study. Ann Oncol 2001;12(12):1737-41.
Abstract
|
